GLP1R and metabolic dysfunction-associated steatohepatitis: These observations spurred interest to engage glucagon receptor agonism in unimolecular formulation with GLP-1R agonism for the treatment of obesity, diabetes, and metabolic dysfunction-associated steatohepatitis (MASH) [295].